🧬 Are Vaccines for Aspergillosis on the Horizon?

If you live with aspergillosis—whether it’s ABPA (Allergic Bronchopulmonary Aspergillosis), CPA (Chronic Pulmonary Aspergillosis), or invasive aspergillosis—you’ve probably wondered if a vaccine might one day help prevent or control this condition. As of 2025, there is no licensed vaccine for any form of aspergillosis, but scientists are actively working on it.

This article explains where things stand, what’s being developed, and what it could mean for people like you.

---

🦠 What is Aspergillosis?

Aspergillosis is a group of illnesses caused by the fungus Aspergillus fumigatus. It’s very common in the environment, especially in soil, dust, and decaying vegetation. Most people breathe in the spores without getting sick, but if you have:

• Damaged lungs (due to asthma, COPD, or TB)

• A weakened immune system

• An allergic reaction to fungal spores

…you may develop a form of aspergillosis, such as:

• ABPA – a severe allergic lung condition

• CPA – long-term fungal infection in damaged lungs

• Invasive aspergillosis – a fast-moving, life-threatening infection in immunocompromised people

---

💉 Why Develop a Vaccine?

A vaccine could:

• Prevent serious illness in high-risk people (like cancer or transplant patients)

• Reduce allergic sensitisation in ABPA

• Lower the need for long-term antifungal drugs, which can have side effects and lose effectiveness

• Protect against lung damage caused by repeated infections

But making a vaccine isn’t easy—especially for a disease that behaves differently depending on a person’s immune system.

---

🧪 Vaccines in Development (2025)

While none are yet available for patients, several experimental vaccines are being tested in laboratories and early-stage trials. Here are the most promising ones:

---

1. NDV-3A Vaccine

• Originally developed for a yeast infection (Candida albicans)

• Found to trigger cross-protection against Aspergillus fumigatus

• Uses a protein called Als3p, shared between fungi

• Completed early safety trials for Candida

• Being explored for people with weak immune systems, like transplant recipients

---

2. AF.KEX1 DNA Vaccine

• Uses a fungal protein called Kexin 1

• Delivered as a DNA vaccine to help the body produce protective immune cells

• Shown to work well in animal models

• Designed to help high-risk patients, such as those having chemotherapy

---

3. Asp f3 Protein Vaccine

• Focuses on a specific Aspergillus protein (Asp f3)

• Stimulates T-helper cells (Th1 and Th17), important for fighting fungal infections

• Still in preclinical stages, but results in mice are promising

---

4. Nasal Spray Vaccine with Nanoparticles

• Uses chitosan (a natural substance) to deliver the vaccine via the nose

• Aims to stimulate mucosal immunity (lining of the lungs and airways)

• Could be useful for people with ABPA or cystic fibrosis, who often have fungal colonisation in the lungs

---

5. Exploratory mRNA Vaccines

• Inspired by COVID-19 vaccine technology

• Still experimental, but may offer faster, more targeted vaccine design

• No clinical trials yet, but research is underway

---

🚧 Why Don’t We Have a Vaccine Yet?

Developing a vaccine for aspergillosis is challenging:

• The immune response needed varies between allergic, chronic, and invasive forms

• Many people most at risk (e.g. after organ transplant) are too immunocompromised to respond well to vaccines

• Aspergillus has many different proteins—no single target works for everyone

• Research funding is often limited, because aspergillosis is considered rare

---

👥 Who Might Benefit Most?

A future vaccine could be life-changing for:

• People with weakened immune systems (e.g. after stem cell or organ transplant)

• People with long-term lung disease, including ABPA and CPA

• Children and adults with cystic fibrosis

• People undergoing chemotherapy or immune-suppressing treatment

---

🗣️ What Can Patients Do?

You can help push this research forward:

• Join a registry or research study if asked by your hospital

• Share your story with groups like the National Aspergillosis Centre (NAC) or Rare Disease UK

• Support advocacy efforts calling for better funding of fungal research

• Stay up to date with trial opportunities on trusted sites like aspergillosis.org

---

📌 Key Takeaways

---

🧭 Looking Ahead

Although no vaccine is available yet, the science is moving forward — thanks to global research teams who see the impact aspergillosis has on patients’ lives. Even small steps now could lead to major breakthroughs in future care.

Your voice matters. Stay connected, stay informed — and keep asking for more focus on this important condition.

Path: Start » Living with Aspergillosis » General interest » 🧬 Are Vaccines for Aspergillosis on the Horizon?